| Dr Sean Patrick Hopper, DO | |
|
7101 S Padre Island Dr, Graduate Medical Education, Corpus Christi, TX 78412-4913 | |
| (361) 761-3280 | |
| Not Available |
| Full Name | Dr Sean Patrick Hopper |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 7101 S Padre Island Dr, Corpus Christi, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467793034 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | BP10042479 (Texas) | Secondary |
| 208D00000X | General Practice | P8253 (Texas) | Primary |
| 207P00000X | Emergency Medicine | P8253 (Texas) | Secondary |
| Entity Name | Pinnacle Emergency Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982664801 PECOS PAC ID: 4880671882 Enrollment ID: O20050120000060 |
News Archive
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse's cancer was incurable, or they heard this information during the last week of her life.
InDevR Inc., a Boulder-based analytical technology and life science company, today announced plans to launch a Research Use Only version of their FluChip-8G technology to aid in pandemic preparedness.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new EU project, METSY, develops and applies neuroimaging and bioinformatics tools to study how lipid metabolism is connected to psychotic disorders and metabolic co-morbidities such as metabolic syndrome and diabetes.
› Verified 9 days ago
| Entity Name | Guadalupe Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114425220 PECOS PAC ID: 0941561781 Enrollment ID: O20180219001747 |
News Archive
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse's cancer was incurable, or they heard this information during the last week of her life.
InDevR Inc., a Boulder-based analytical technology and life science company, today announced plans to launch a Research Use Only version of their FluChip-8G technology to aid in pandemic preparedness.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new EU project, METSY, develops and applies neuroimaging and bioinformatics tools to study how lipid metabolism is connected to psychotic disorders and metabolic co-morbidities such as metabolic syndrome and diabetes.
› Verified 9 days ago
| Entity Name | Emergency Medicine Services Of Tx Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245938729 PECOS PAC ID: 3375909351 Enrollment ID: O20230517001124 |
News Archive
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse's cancer was incurable, or they heard this information during the last week of her life.
InDevR Inc., a Boulder-based analytical technology and life science company, today announced plans to launch a Research Use Only version of their FluChip-8G technology to aid in pandemic preparedness.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new EU project, METSY, develops and applies neuroimaging and bioinformatics tools to study how lipid metabolism is connected to psychotic disorders and metabolic co-morbidities such as metabolic syndrome and diabetes.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sean Patrick Hopper, DO 7101 S Padre Island Dr, Graduate Medical Education, Corpus Christi, TX 78412-4913 Ph: () - | Dr Sean Patrick Hopper, DO 7101 S Padre Island Dr, Graduate Medical Education, Corpus Christi, TX 78412-4913 Ph: (361) 761-3280 |
News Archive
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse's cancer was incurable, or they heard this information during the last week of her life.
InDevR Inc., a Boulder-based analytical technology and life science company, today announced plans to launch a Research Use Only version of their FluChip-8G technology to aid in pandemic preparedness.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new EU project, METSY, develops and applies neuroimaging and bioinformatics tools to study how lipid metabolism is connected to psychotic disorders and metabolic co-morbidities such as metabolic syndrome and diabetes.
› Verified 9 days ago
Dr. Facundo Gaston Gonzalez, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 7101 S Padre Island Dr, Corpus Christi, TX 78412 Phone: 305-316-4010 | |
Elisadel Figueroa, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 3315 S Alameda St, Corpus Christi, TX 78411 Phone: 361-761-1000 Fax: 361-884-2919 | |
Dr. James Keith Rose, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 5536 Saratoga Blvd, Corpus Christi, TX 78413 Phone: 361-992-0227 Fax: 361-992-0669 | |
Dr. Susan Comer, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 15394 Caravel Dr, Corpus Christi, TX 78418 Phone: 361-949-7468 Fax: 361-949-7468 | |
Kristie Ann Robson, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 10651 E St, Corpus Christi, TX 78419 Phone: 361-961-4311 | |
Clark Hayden Stearns, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 6031 Lost Creek Drive, Corpus Christi, TX 78413 Phone: 361-288-3528 | |
Dr. Thomas Milligan, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 3533 S Alameda St, Corpus Christi, TX 78411 Phone: 361-694-5427 |